Related Experiment Video
Updated: Aug 29, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Assessing predictors of drug-induced torsade de pointes
Luiz Belardinelli1, Charles Antzelevitch, Marc A Vos
1CV Therapeutics, 3172 Porter Drive, Palo Alto, CA 94304, USA. luiz.belardinelli@cvt.com
Abstract:
Torsades de pointes (TdP) is a malignant polymorphic ventricular tachyarrhythmia that can be caused by drugs that induce electrophysiological changes. Although the number of drugs known to cause TdP has increased in recent years, there is no cell-based assay, in vitro heart preparation or animal model that predicts the potential of a drug to induce TdP in humans. Nevertheless, certain electrophysiological events are known to be associated with the development of TdP. For example, a drug that prolongs action potential duration, induces early afterdepolarizations and ectopic beats, and increases dispersion of ventricular repolarization is likely to cause TdP. By contrast, a drug that does not induce these changes is unlikely to cause TdP. The exact relationship between these electrophysiological events and the development of TdP has not been defined, but the potential of a drug to elicit these events might predict its pro-arrhythmic risk.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Therapeutic Drug Monitoring: Affecting Factors
Drug Toxicity: Risk factors
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Dysrhythmias V: Evaluating Dysrhythmias
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers